Medical Encyclopedia

Acute Myeloid Leukemia (AML)

A blood cancer requiring urgent treatment but with improved prognosis thanks to modern therapies. This guide explains types, risk factors, symptoms, diagnosis, and treatment strategies.

Medical researcher working in a clinical laboratory
Not medical advice. AML requires urgent treatment. If you have symptoms like unexplained fever, severe fatigue, or unusual bleeding, seek immediate medical care.
At a Glance

Quick Overview

Annual Incidence

Approximately 20,000 new cases per year in the United States. Most common acute leukemia in adults. [ACS, 2024]

Requires Urgent Treatment

AML is a rapidly progressive disease. Diagnosis requires immediate treatment initiation, typically within days. [NCI, 2024]

Median Age at Diagnosis: 68

Most common in older adults, though can occur at any age. Treatment approach varies based on age and fitness. [ACS, 2024]

Complete Remission Possible

50-80% of patients achieve complete remission with modern treatment. Survival rates have improved significantly. [NCCN, 2024]

Understanding the Basics

What Is Acute Myeloid Leukemia?

AML is a blood cancer where the bone marrow produces too many immature myeloid cells (blasts), overwhelming normal blood cell production. This leads to anemia (low red cells), infections (low white cells), and bleeding problems (low platelets). Unlike slowly progressive diseases, AML is fast-moving and requires prompt treatment. However, modern therapies offer much better outcomes than in the past, with many patients achieving long-term remission. [NCI, 2024]

The key to AML management is understanding your cytogenetic and molecular profile — the specific genetic mutations in your leukemic cells — because this determines prognosis and guides treatment selection.

Classification

AML Types & Genetics

Cytogenetic Categories

AML is classified by chromosome patterns. Favorable cytogenetics (translocations like t(15;17), t(8;21)) have better prognosis. Unfavorable cytogenetics (complex karyotype, -5, -7, TP53 mutations) require more intensive treatment. [NCCN, 2024]

Molecular Mutations

Testing for mutations (FLT3, NPM1, IDH1, IDH2, TP53, etc.) guides prognosis and treatment selection. Some mutations respond to targeted therapy. Mutation profiling is now standard for all AML. [ACS, 2024]

Treatment-Related AML

AML that develops after prior chemotherapy or radiation (secondary AML) has worse prognosis and different treatment options, often hypomethylating agents rather than intensive chemotherapy. [NCI, 2024]

APL (Acute Promyelocytic Leukemia)

A specific AML subtype with t(15;17) translocation. Highly curable with targeted treatment (ATRA and arsenic trioxide), with cure rates exceeding 80%. Rapid diagnosis and treatment are critical. [ACS, 2024]

Finding the Answer

Diagnosis & Testing

Blood Tests & CBC

Initial blood work shows elevated blast count (immature cells), anemia, low white count, and low platelets. [NCI, 2024]

Bone Marrow Biopsy & Aspirate

Definitive diagnosis requires bone marrow sample showing 20%+ blasts. Samples are sent for cytochemistry, flow cytometry, cytogenetics, and molecular testing. [ACS, 2024]

Cytogenetics & Molecular Testing

Chromosome analysis, fluorescence in situ hybridization (FISH), and DNA mutation testing determine prognosis and treatment eligibility. Essential for all AML patients. [NCCN, 2024]

Imaging

CT or MRI may assess organ involvement. Lumbar puncture checks for leukemia in the central nervous system. [NCI, 2024]

Your Treatment

AML Treatment Approaches

Intensive Chemotherapy (Induction)

Standard regimen is "7+3" (cytarabine for 7 days + daunorubicin for 3 days). Goal is complete remission (CR). Recovery typically takes 3-4 weeks. Intensive therapy is standard for younger, fit patients. [NCCN, 2024]

Hypomethylating Agents

Azacitidine or decitabine are often used in older or unfit patients, given as outpatient therapy. May take months to achieve response but have fewer side effects than intensive chemotherapy. [ACS, 2024]

Targeted Therapy

FLT3 inhibitors (for FLT3-mutant AML), IDH inhibitors (for IDH1/2-mutant AML), and venetoclax (often combined with hypomethylating agents) offer personalized treatment based on mutations. [NCI, 2024]

Consolidation & Stem Cell Transplantation

After achieving remission, consolidation chemotherapy or stem cell transplant helps prevent relapse. Transplantation considered for high-risk disease or after first relapse. [NCCN, 2024]

Supportive Care

Antibiotics, blood transfusions, and platelet support are essential during treatment. Infection prevention and management are critical. [ACS, 2024]

Challenges of Treatment

Side Effects & Complications

Infection Risk

Severe immunosuppression during chemotherapy creates infection risk. Prophylactic antibiotics and careful monitoring are standard. Fever warrants immediate medical attention.

Chemotherapy Toxicity

Nausea, mouth sores, hair loss, diarrhea, and organ damage (cardiac, renal, hepatic) can occur. Supportive medications help manage symptoms.

Fatigue & Anemia

Severe fatigue is universal during treatment. Blood transfusions support red cell counts. Fatigue typically improves with remission.

Emotional & Psychological Toll

AML diagnosis is devastating. Fear, anxiety, and depression are common. Counseling and support groups are important resources.

Evidence Base

Sources & References

  1. American Cancer Society (ACS). "Acute Myeloid Leukemia Overview." Cancer.org. Accessed 2024.
  2. National Cancer Institute (NCI). "Acute Myeloid Leukemia Treatment (PDQ)." Cancer.gov. Accessed 2024.
  3. National Comprehensive Cancer Network (NCCN). "NCCN Guidelines: Acute Myeloid Leukemia." Version 1.2024.

Last reviewed: February 2025. Not medical advice. Always consult your care team.